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Abstract
Background
This study was undertaken to assess the long term outcome on the quality of life of patients with sciatica following
treatment with chemonucleolysis, and to assess the complications.
Methods
This is a retrospective review carried out in a consecutive group of patients suffering from sciatica treated by
chemonucleolysis. Patients were followed up by questionnaires to obtain Macnab score; satisfaction, SF 36, and
case note review for complications and repeat spinal surgery.
Results
Six hundred and five patients (56% males, 44% females) treated over a ten year period from 1991 to 2000 were fol-
lowed up. Average age was 47 years (range 17 - 88 years). The duration of symptoms prior to treatment averaged 10
months (range 1 - 20 months) and the herniation was confirmed by Myelogram (7%), CT Scan (34%), or MRI (59%).
There were 578 single level and 27 double levels treated. Eighty five percent of herniations were typical single level
, and 15% were atypical that is: patients with dominant back pain with sciatica, recurrent herniations following
surgery at the same level, recurrent herniations at another level following chemonucleolysis, double levels treated
patients with mainly neurological deficits and one cauda equina syndrome. Average follow up was 62 months
(range 12 - 123) with a 78% satisfaction rate, with a 14% surgical intervention rate made up of 9% decompression, 1%
repeat chemonucleolysis at another level and 4% fusion rate. SF-36 scores generally correlated with age and sex on
scores for the normal local population.
Conclusions
This is a retrospective study and showed that chemonucleolysis was effective with a high satisfaction rate. It re-
stores quality of life close to that expected in the population, and is safe with no complications related to the proce-
dure. It is a cost effective daycase procedure with a lasting result.
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Introduction
Chymopapain chemonucleolysis was and is poten-
tially an excellent method of treatment that is cur-
rently being denied to patients suffering from sciatica
due to a soft disc herniation. Chymopapain
chemonucleolysis was first reported by Lyman Smith
in 1964 and the first product called Discase was man-
ufactured by Smith Laboratories Inc. It became wide-
ly used throughout Europe, North America and Aus-
tralia1-16 and was demonstrated to be an effective and
safe method of treatment. The enzyme chymopapain
is injected by the lateral route into the center of the
nucleus with digestion of the proteoglycan of the nu-
cleus and the herniation, the products being excreted
in the urine.17,18,19 A purer preparation (Chymodi-
actin, Smith Laboratories Inc. USA) was later intro-
duced due to a risk of anaphylaxis and its efficacy has
been established in many randomized studies com-
pared to a placebo;20-23 and to surgery.24-27 In 2001 two
excellent review papers described the history and sta-
tus of the procedure.28,29 Unfortunately the enzyme
ceased to be available in 2002 for non-scientific com-
mercial reasons.
In 1995 Boots Pharmaceuticals, based in Notting-
ham, U. K. manufactured, owned and marketed the
product. Their training and clinician support was
second to none and uptake of the treatment in the
United Kingdom was increasing by 30% annually. For
financial reasons, they sold the phamaceutical busi-
ness to BASF, based in Germany, who decided to
move the manufacture from Nottingham in the U. K.
to Germany. In 2000, BASF then sold, part of their
pharmaceutical business to Abbot Pharmaceuticals
before the lab had transferred. Abbot consulted wide-
ly whether to proceed with the laboratory setup and
in the end, decided not to go ahead. Eventually
stocks of Chymodiactin ran out.
Open surgery (micro- or standard discectomy) to re-
move the herniation entrapping the nerve root, re-
mains the treatment of choice, often with removal of
much of the remaining nucleus.30-38 Excellent results
can be achieved but it remains a major operative pro-
cedure with a risk of complications and recur-
rence.39-45 Attempts to reduce the risks have led to the
development of less invasive techniques.46-51 Sadly
the least invasive technique of chymopapain
chemonucleolysis, remains unavailable.
The author carried out over 2,000 chemonucleolysis
procedures over a twenty year period, from 1982 to
2002. He introduced the procedure by means of a
prospective randomized study of 100 consecutive pa-
tients with al follow up of one, 10-13, and 24-27 years
demonstrating no difference in either the clinical or
radiological outcomes.52,53 This paper reports the re-
sults of a consecutive cohort of patients over a ten
year period (who would otherwise have been consid-
ered suitable for discectomy), treated by chymopa-
pain chemonucleolysis. There was no selection based
on age, size of herniation or level, but simply on the
patient’s symptoms of dominant leg pain, with or
without neurological signs and demonstrated to be
due to a herniated disc by an appropriate spinal in-
vestigation.
Material and Method
This is a retrospective review of six hundred and five
patients treated by the author collated from a review
of the operating lists during the period 1991 to 2000,
and whose case notes were available for review. Pa-
tients were assessed according to the Macnab Crite-
ria (Table 1). All patients had at least three months of
non-operative care with analgaesics, relative rest, and
physiotherapy and if not significantly improved, they
were offered chemonucleolysis. They had dominant
leg pain with or without low back pain, restricted
Straight leg raising and an investigation demonstrat-
ing a causative herniation. Having symptoms requir-
ing surgery prior to chemonucleolysis, I believe that
they are all are all classified as poor on Macnab Crite-
ria. Complications and long term outcome including
the impact of chemonucleolysis on quality of life of
patients with sciatica were assessed. The case
records were reviewed for details of presentation,
past history of spinal treatments, radiological investi-
gations, peri-operative and post operative complica-
tions and subsequent procedures if any. Patients were
sent questionnaires to allow follow up assessment of
Macnab Criteria, whether satisfied or not satisfied
with treatment and an SF36 to allow comparison of
Quality of life to the local norm.
Technique of Chemonucleolysis
All patients were offered active intervention if symp-
toms have not improved following an adequate peri-
od of conservative treatment of 6 – 12 weeks and
were then listed for the procedure. During the years
2001 to 1995, patients had an overnight stay in Hos-
pital, and from 1995 – 2000 the procedure was per-
formed as a day case. Patients were admitted early in
the morning. One hour before the procedure 10 -15
mg of Cyclimorph (morphine tartrate 10 or 15 mg
with cyclizine tartrate 50mg/ml) was given by intra-
muscular injection depending on the patient’s
Table 1. Macnab Criteria (Macnab I. “negative disc exploration: an
analysis of the cause of nerve root involvement in sixtyeight patients.” J
Bone Joint Surg (Am) 1971 ;53:891-903).
• Excellent: No pain; no restriction of activity.
• Good: Occasional back or leg pain of sufficient severity to interfere
with the patient’s ability to do his normal work or his capacity to enjoy
himself in his leisure hours.
• Fair: Improved functional capacity, but handicapped by intermittent
pain of sufficient severity to curtail or modify work or leisure activities.
• Poor: No improvement or insufficient improvement to enable increase
in activities; further operative intervention required.
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weight. In the anaesthetic room, a large bore IV was
inserted, and through this 2cc Midazolam hydrochlo-
ride was given as sedation and the patient, was posi-
tioned on the operating table, with a single arm im-
age intensifier, positioned so that simply swinging it
through 90 degrees gave a true AP and lateral view of
the disc. Ten ml of bupivacaine was injected into the
skin and muscle down to the disc. An 18 guage nee-
dle passed down to the postero-lateral corner of the
disc and then a 22 gage needle passed through it rail-
road fashion into the center of the nucleus. A discog-
raphy was performed with a non-ionic contrast (Om-
nipaque 240 mgm/ml) by slow injection of 0.5cc to
demonstrate the dye entering the disc (and often, the
herniation). A small amount of propofol (Diprivan,
AstraZeneca) was titrated via the IV, just enough to
make the patient still, co-operative and amnesic, then
one cc of Chymodiactin (2000 I U) was slowly inject-
ed. Patients always awoke rapidly and routine moni-
toring continued in the recovery room for two hours
and discharged an hour or two later with a progress
advice sheet. An assessment carried out in the recov-
ery area within one hour of the procedure in 50 pa-
tients showed that 31 of them (60%) had complete or
greatly reduced leg pain with a corresponding reduc-
tion in straight leg raising (unpublished data). The
rest had moderate or no improvement at that time
point.
Results
Review of the case records
The case records contained a description of the pa-
tient’s pain distribution, and also a pain drawing
which demonstrated clearly the distribution of symp-
toms. Also records of previous history of back pain or
back pain surgery and size and position of the hernia-
tion. From this the presentation of the patients were
classified into typical and atypical presentations.
Therefore a typical presentation was a patient, with
no previous history of spinal surgery, with dominant
leg pain with or without back pain and with or with-
out neurological changes who had restricted straight
leg raising and a disc herniation within the spinal
canal or lateral recess. These numbered 515 patients
(85%).
The atypical presentations numbered 90 patients
(15%) are as follows:. (1) Dominant back pain with leg
pain (34 patients). (2) Patients who had dominant leg
pain due to a far lateral or foramenal herniation (14
patients). None of these required subsequent
surgery. (3) Patients who had symptoms due to a re-
current herniation following previous discectomy (11
patients). All of these Patientshad relief of leg pain.
(4) patients who had minimal leg pain but who had
severe neurological symptoms such as a complete
drop foot, marked weakness of foot plantar flexion or
quadriceps weakness usually accompanied by paraes-
thesia or numbness in the same dermatome or der-
matomes (3 patients). All of these patient had a rapid
improvement immediately following chemonucleoly-
sis and none of them had subsequent surgery. (5)
Two level herniations in patients who had leg pain
often with significant back pain, with herniations pre-
sent at two adjacent lumbar levels. Often the symp-
toms would suggest one particular level, but in gen-
eral both levels were injected. The majority of these
patients who also had significant back pain prior to
injection, ultimately had a two level fusion per-
formed. (6) one patient had a cauda equina syndrome
(Table 2).
All patients were managed routinely as described
above apart from the patient with cauda equina syn-
drome. He presented with acute onset of bilateral an-
terior thigh pain, weakness of thigh muscles and
numbness thighs and legs over two weeks. On admis-
sion, he was unable to stand unaided and bladder and
bowel function were intact with numbness extending
to the saddle area. He had a previous history of left





Leg pain with significant back pain 34 (6%)
Far lateral/foraminal herniation 14 (2%)
Recurrent disc herniation following surgery 3 (0.5%)
dominant neurology with minimal leg pain 3 (0.5%)
two level herniations 27 (4%)
Cauda equina syndrome 1 (0.1%)
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my some years previously, and a recurrent right sided
prolapse with a repeat discectomy leaving him with a
right drop foot for which he used an orthosis. His
MRI scan demonstrated a midline extra dural lesion
at L2/3 thought most likely to be a disc herniation. A
discography was performed with a non-ionic contrast
(Omnipaque 240 mgm/ml) by slow injection of 0.5cc
demonstrated the dye entering the herniation. The
patient was sedated and one cc of Chymodiactin
(2000 I U) was slowly injected over two minutes and
was monitored closely for any neurological changes.
He was subsequently able to stand unaided after 5
days, and at 3 months had fully recovered and re-
turned to his non manual work. His pain score
changed from 7.5 to 3.5 and his ODI from 80 to 38.
The average age of the patients was 47 years of age
(range 17 – 88 years). Fifty six percent were male and
44 % female. The average duration of symptoms was
10 months (range 1-120 months),with right sided leg
pain in 51% and left in 49%. During this period of time
the availability of radiological investigation changed
so that it was a myelogram in 42 patients, a CT scan
in 206 and an MRI scan in 357 patients. We feel that
the choice of investigation made little or no differ-
ence to the diagnosis as the primary reason for con-
sidering intervention was the patients symptoms
(Table 3).
The majority of levels treated were single level at L5/
S1 (296) and L4/L5 (264) with a small number at
L3/4 (16) and L2/3 (2). Twenty seven double levels
were treated where there were two level herniations
with at least one on the same side with the possibility
that one or other or both of these levels were the
cause of symptoms. Also typically these patients had
a greater tendency to have a greater degree of low
back pain in relation to leg pain, and were advised
Table 3. Patient Demographics (605 cases, 1991-2000).
that they were at a greater risk of failure (Table 4).
The average follow up was 62 months, ranging from
12 to 123 months (Table 5). Seventy six percent of
patients had good or excellent Macnab scores includ-
ing those who had subsequent surgery and this
equated well with 78 percent of patients who were
satisfied with their result. The SF36 scores were
compared by age and sex to the normal values for the
local population. The relative study numbers were
small, and in general equated closely to the normal
local values. Eighty four patients (14 %) had subse-
quent surgery. Twenty four patients (4%) had fusion
for persistent disabling chronic low back pain persist-
ing for more than six months following chemonucle-
olysis. . The majority were two level cases and some
patients who presented with dominant back pain be-
fore injection and were therefore not ideal candidates
for chemonucleolysis. Fifty four patients (9%) had a
decompression for persistent leg pain demonstrated
by imaging to be due to persistent herniation. It is the
author’s experience that those patients tended to
have a long history of leg pain, or had large hernia-
tions as shown in a previously previously randomised
study conducted in the unit.52,53 None of these pa-
tients were from the recurrence following surgery
and foramenal or far lateral herniation groups. Six pa-
tients (1%) had a further disc herniation at the adja-
cent or other level than the primary one treated by
chemonucleolysis.
Complications
There were no complications related to the proce-
dure (Table 6). Eight patients had readmission to
hospital, three of these for suspected deep venous
thrombosis following surgery, and the rest for per-
sisting back pain following two level chemonucleoly-
sis who ultimately went on to have an instrumented
Table 4. Distribution of injections.
Mean Age 47 years (range 17-88)
Sex M 56% W 44%
Duration of Symptoms 10 months (range 1 - 120)
Radicular pain Right (51%); left (49%)
Investigation
Myelogram 42 patients;






L4-5 & L5-S1 25
L3-4 & L4-5 2
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fusion. There were no cases of infection, no neuro-
logical complications no cases of anaphylaxis, and no
recurrent herniations at the same level. Six patients
had a second herniation at another level, all treated
by chemonucleolysis (Table 3); one patient had a fall
in blood pressure which was corrected by infusion of
one and a half litres of normal saline and without ad-
ditional medication. He recovered normally there-
after. Because of the potential risk of sensitisation,
these patients were premedicated with Chlorpheni-
ramine maleate 6 mgs every six hours for 24 hours
prior to the procedure to protect against possible
anaphylaxis, accepting that this might alleviate the
severity of anaphylaxis, but not prevent it.
Prior to this series, the author had trialled a series of
over 300 patients who were RAST tested for allergy
to chymopapain, prior to chemonucleolysis. Two suf-
fered mild skin rashes (one RAST negative and one
showing mild positive reaction) One patient had an
anaphylactic reaction, the only one of over 2,000
procedures, and she was RAST negative. The use of
the RAST test was discontinued. It is essential that
all patients have a large bore IV inserted prior to the
procedure to allow for rapid infusion on the rare oc-
casion it may be necessary. In over 2,000 cases there
was one case of discitis following injection. Two pa-
tients had a reduced blood pressure corrected by IV
fluids; one had mild facial swelling and two mild skin
Table 5. Results.
SF-36 scores generally correlated with age/sex of normal scores for the
local population.
Table 6. Complications.
rashes occurred, in total 7 complications attributable
to chemonucleolysis.
Discussion
This paper describes a consecutive series of patients
presenting to a single spinal unit treated by
chemonucleolysis who would equally have been con-
sidered suitable for surgical discectomy At least one
half of them were treated as a day case once it was re-
alised that it was a suitable option. Seventy eight per-
cent of patients were satisfied with their outcome
which compares exactly with satisfaction outcomes
for discectomy at 2 years in data from the Swedish
Spine Registry.55 The registry does not report the in-
cidence of recurrent herniations, but shows that 12
per cent of patients who have a discectomy had pre-
vious spinal surgery.55 No patients in this series had a
recurrent herniation at the same level and this is sig-
nificant considering that the recurrence rate at the
same level following discectomy varies from 5 to over
27% within two years with an average of 5 and 10% at
one and ten years.56,57,58 Aggressive discectomy re-
duces the risk but increases the longterm incidence
of back and leg pain.59,60 Annular closure devices have
been developed in an attempt to reduce the hernia-
tion level but the results are not conclusive.61 Nine
per cent of patients did have surgery for continuing
leg pain that had failed to subside within a reasonable
time usually around 3 months and 91% of patients
therefore did not require decompression surgery for
their disc herniation. A feature of surgery at the same
level following failed chemonucleolysis is that there
is no fibrosis whatsoever in contrast to surgery for re-
current herniation where fibrosis and scar results in
increased complications. Attempts to reduce the fi-
brosis have been tried but results are inconclusive.62,63
It has been previously shown that disc herniations
occur at all ages and the degree of degenerative
change in this group of patients is unrelated to age.54
Also failures of chemonucleolysis occur most often
in younger patients.53 The pathology and presenta-
tion of acute disc herniation, as described in the ma-
terials and method, is quite different from that of
spinal stenosis which is a chronic degenerative
process, or spondylolisthesis. Four percent of pa-
tients in this series did go on to a spinal fusion due to
persistent back pain following the chemonucleolysis
Average Follow-up 62 months (range 12 - 123)
Macnab (Excellent and Good) 76%
Satisfaction 78%
Surgical Intervention 14%
Fusion/Stabilisation 4% (24 patients)
Decompression 9% (54 patients)
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procedure. These patients were all either two level
cases or had dominant back pain prior to chemonu-
cleolysis and were therefore not ideal candidates.
Publications of treatments for disc herniation do not
report the subsequent numbers of patients who after-
wards require a spinal fusion. However, the Swedish
Spine Registry reports that 35 percent of patients
who have a spinal fusion have had previous spinal
surgery.55 It is likely that many of these had a previ-
ous discectomy. The outcome of decompression
surgery for lumbar herniated disc is influenced by the
level of concomitant preoperative low back pain64 and
similarly the author has documented similarly that a
poorer outcome is to be expected in patients with sig-
nificant low back pain prior to chemonucleolysis.
There were no significant complications due to the
procedure in this series of 605 patients; no infec-
tions, no neurological complications and no anaphy-
laxis although in over 2000 cases treated in the unit,
there were two notable complications, one of ana-
phylaxis and one of infection. The other minor reac-
tions, such as a drop in blood pressure, could have
been due to medications or factors other than the
chymopapain. Nordby et al reported that during the
period 1982 – 1991, there were 121 adverse events re-
ported to the FDA out of 135,000 patients, that is a
complication rate of 0.09%.65 He compared those to
the largest series of surgical complications published
by Ramirez and Thisted where the overall complica-
tion rate was 1.13%.66 On these figures surgery has
over twelve times the complication rate of chemonu-
cleolysis. Dural tear is a complication of discectomy
by whatever means, standard open, micro MIS endo-
scopic and endoscopic foraminal.67-71 It usually does
not have long term sequelae but the rare occurrence
of CSF leak and iatrogenic meningoceal causes sig-
nificant morbidity.72-75 Teli et al compares MIS endo-
scopic treatment with micro, and standard surgery
and found increased dural tears in endoscopic discec-
tomy.76 In addition, Minimally Invasive Surgery does
not decrease muscle damage as claimed compared to
conventional surgery.77 Chymopapain is injected usu-
ally using an 18 guage (1.27 mm) needle. Ozone treat-
ment is the only other minimal intervention treat-
ment available with a similarly low complication rate
to chemonucleolysis, but has had less usage and no
long term follow up beyond two years.78 Finally in the
USA, authors have shown significantly reduced costs
comparing chemonucleolysis to surgery, taking all
factors into account including further surgery.79
This paper demonstrates that chemonucleolysis is a
day-case procedure requiring a short operative time
compared to surgery, which generally also requires
an overnight stay. Nine percent of patients require
surgery in the form of a decompression which com-
pares favourably to surgery where 5 to 21 % may re-
quire a second surgery for a recurrent herniation.
Conclusion
Chemonucleolysis therefore is the most cost effec-
tive, least invasive and safest treatment available for
soft disc herniation with an equal efficacy to other
treatments; and has a large body of literature to sup-
port this. We owe it to our patients to make it avail-
able as a treatment.
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